Lakewood-Amedex Biotherapeutics Completes Redemption of Series C Convertible Preferred Stock
Lakewood-Amedex Biotherapeutics Inc. has finalized the redemption of all remaining outstanding shares of its Series C Convertible Preferred Stock.
Stocks · News reference
Lakewood-Amedex Biotherapeutics Presents Research Highlighting Antimicrobial Profile Of Nu-3, Lead Clinical Candidate, At IDWeek 2026; Topline Data From Trial Expected In Q1 2027
Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcersSARASOTA, Fla., Oct. 21, 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.
HC Wainwright Initiates Coverage on Lakewood-Amedex Biotherapeutics With Buy Rating
HC Wainwright has initiated research coverage on Lakewood-Amedex Biotherapeutics Inc. with a Buy rating.
LABT stock has given up its prior gain. Lakewood-Amedex Biotherapeutics shares were trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
Lakewood-Amedex Says Nu-8 Shows Up To 97% Inhibition Of E. Coli Growth In Rodent Urinary Tract Infection Model